Sodium–glucose cotransporter 2 inhibitors (SGLT2is) are a new class of antidiabetic drug that inhibits renal tubular sodium–glucose reabsorption without stimulating insulin release in patients with type 2 DM (T2DM) [5]. This evidence concerns the gene INS and type 2 diabetes mellitus.